A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZBIO SEC filings page.
Zenas BioPharma, Inc. (ZBIO) reported $10.0M in revenue for fiscal year 2025, up 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ZBIO is funding a development-stage cost base externally: revenue remains small while research spending and operating cash needs expand.
External financing exceeded operating cash use in FY2024, with financing of$413M versus operating cash flow of-$120M . In FY2025, financing fell to$215M while operating cash flow reached-$172M , showing that outside funding remained central as internal cash needs approached the financing inflow.
Revenue doubled from
Cash consumption is primarily operating rather than physical expansion: FY2025 operating cash flow was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Zenas BioPharma, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Zenas BioPharma, Inc. held $360.5M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $172.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Zenas BioPharma, Inc. scores 54/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Zenas BioPharma, Inc. scores 4/100 on it among other emerging companies.
Zenas BioPharma, Inc. spent $168.1M on research and development in fiscal year 2025, which was 42.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Zenas BioPharma, Inc. scores 72/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Zenas BioPharma, Inc. scores 4/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Zenas BioPharma, Inc. scores 6/100 on it among other emerging companies.
Zenas BioPharma, Inc.'s cash, cash equivalents and investments came to $360.5M at the end of fiscal year 2025, against $141.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Zenas BioPharma, Inc. scores 79/100 among other emerging companies.
Zenas BioPharma, Inc. scores 2.44, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $1.8B against total liabilities of $141.5M. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Zenas BioPharma, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
Zenas BioPharma, Inc. reported a net loss of $377.7M while operations used $172.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Zenas BioPharma, Inc. reported an operating loss of $383.1M against $7.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Zenas BioPharma, Inc. generated $10.0M in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 900.0%.
Zenas BioPharma, Inc.'s EBITDA was -$103.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Zenas BioPharma, Inc. reported a net loss of $108.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Zenas BioPharma, Inc. earned -$1.65 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Zenas BioPharma, Inc. recorded an outflow of $58.0M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Zenas BioPharma, Inc. held $177.8M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Zenas BioPharma, Inc.'s quarterly ROE was -51.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 25.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.2 percentage points.
Not reported for Q3 2026.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Zenas BioPharma, Inc. invested $58.5M in research and development in Q3 2026. This represents an increase of 70.0% from the same quarter a year earlier. Against the prior quarter it is down 7.1%.
Zenas BioPharma, Inc. invested $1K in capex in Q3 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
ZBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.0Mn/m | $1.0Mn/m | N/A | $0 | $0n/m | $0n/m | $10.0M | N/A |
| R&D Expenses | $58.5M+70.0% | $62.9M+46.2% | $60.4M+73.1% | $55.7M+13.3% | $34.4M+2.6% | $43.0M+27.3% | $34.9M+54.2% | $49.2M |
| SG&A Expenses | $27.4M+108.2% | $15.7M+29.7% | $16.9M+36.2% | $15.6M+36.0% | $13.2M+76.8% | $12.1M+105.9% | $12.4M+151.7% | $11.5M |
| Operating Income | -$103.4Mn/m | -$107.7Mn/m | -$77.3Mn/m | -$238.0Mn/m | -$52.6Mn/m | -$55.2Mn/m | -$37.3Mn/m | -$55.6M |
| EBITDA | -$103.4Mn/m | -$107.7Mn/m | -$77.3Mn/m | N/A | -$52.6Mn/m | -$55.2Mn/m | -$37.3Mn/m | N/A |
| Interest Expense | $2.1M | $1.7M | $368K | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $49K | $114K+470.0% | N/A | N/A | N/A | $20K | -$205K | N/A |
| Net Income | -$108.9Mn/m | -$111.5Mn/m | -$81.0Mn/m | -$240.4Mn/m | -$51.5Mn/m | -$52.2Mn/m | -$33.6Mn/m | -$52.6Mn/m |
| EPS (Basic) | -$1.65 | -$1.77 | -$1.46n/m | -$5.17 | -$1.22 | -$1.25 | -$0.80 | N/A |
| EPS (Diluted) | -$1.65 | -$1.77 | -$1.46n/m | -$5.17 | -$1.22 | -$1.25 | -$0.80 | N/A |
| Diluted Shares (Avg) | 66M | 63M | 56M+33.1% | N/A | 42M | 42M | 42M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
ZBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $675.2M+109.7% | $701.7M+139.4% | $747.7M+124.0% | $383.6M+3.7% | $322.0M-20.2% | $293.1M | $333.8M | $370.0M+442.6% |
| Current Assets | $603.4M+103.4% | $653.8M+134.7% | $730.2M+129.8% | $351.2M-1.3% | $296.6M-24.7% | $278.6M | $317.8M | $355.9M+495.1% |
| Cash & Equivalents | $177.8M+53.8% | $196.6M+346.7% | $500.2M+154.5% | $110.6M-65.4% | $115.6M-67.9% | $44.0M-76.1% | $196.6M+429.0% | $319.7M+462.4% |
| Short-Term Investments | $407.5M+132.5% | $446.5M+94.8% | $217.0M+87.3% | $232.6M+649.6% | $175.3M+555.1% | $229.3Mn/m | $115.8Mn/m | $31.0Mn/m |
| Long-Term Investments | $61.8M+476.4% | $30.8M+1806.0% | $1.3M-27.0% | $17.3Mn/m | $10.7Mn/m | $1.6Mn/m | $1.8Mn/m | $0n/m |
| Total Liabilities | $462.9M+268.6% | $454.6M+750.4% | $411.9M+732.9% | $141.5M+146.0% | $125.6M+185.5% | $53.5M | $49.4M | $57.5M-80.4% |
| Current Liabilities | $64.0M+22.2% | $65.8M+23.6% | $61.2M+24.5% | $62.6M+9.4% | $52.4M+19.1% | $53.2M | $49.1M | $57.3M+146.3% |
| Non-Current Liabilities | $398.9M+445.1% | $388.8M+180725.6% | $350.7M+110528.4% | $78.8M+36068.3% | $73.2Mn/m | $215K | $317K | $218K-99.9% |
| Long-Term Debt | N/A | N/A | N/A | $78.6M | $73.0M | N/A | N/A | N/A |
| Total Equity | $212.3M+8.1% | $247.1M+3.1% | $335.8M+18.1% | $242.1M-22.5% | $196.4M-45.4% | $239.6Mn/m | $284.3Mn/m | $312.5Mn/m |
| Retained Earnings | -$1.1Bn/m | -$957.6Mn/m | -$846.1Mn/m | -$765.1Mn/m | -$524.7Mn/m | -$473.2M | -$421.0M | -$387.4Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
ZBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$58.0Mn/m | -$57.2Mn/m | -$75.2Mn/m | -$52.4Mn/m | -$41.1Mn/m | -$41.7Mn/m | -$37.1Mn/m | -$38.6Mn/m |
| Depreciation & Amortization | $4K-63.6% | $4K-66.7% | $6K-73.9% | $10K-69.7% | $11K-69.4% | $12K-65.7% | $23K-30.3% | $33K+10.0% |
| Stock-Based Compensation | $17.3M+135.5% | $8.6M+42.6% | $9.2M+70.7% | N/A | $7.3M+158.0% | $6.0M+293.6% | $5.4M+468.7% | N/A |
| Capital Expenditures | $1Kn/m | $0n/m | $2K-88.9% | $0-100.0% | $0n/m | $0-100.0% | $18K-18.2% | $74K |
| Free Cash Flow | -$58.0Mn/m | -$57.2Mn/m | -$75.2Mn/m | -$52.4Mn/m | -$41.1Mn/m | -$41.7Mn/m | -$37.1Mn/m | -$38.6M |
| Investing Cash Flow | -$19.2M-148.0% | -$287.7Mn/m | $31.6Mn/m | -$93.4Mn/m | $40.0Mn/m | -$112.3Mn/m | -$86.3Mn/m | -$3.7M |
| Financing Cash Flow | $57.2M-21.2% | $42.1M+2342.3% | $433.5M+437757.6% | $140.8M+7500.8% | $72.6M-69.0% | $1.7M-99.0% | $99Kn/m | $1.9M+3606.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ZBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1034.1% | -10765.9% | N/A | N/A | N/A | N/A | -373.3% | N/A |
| Net Margin | -1089.2% | -11145.6% | N/A | N/A | N/A | N/A | -335.7% | N/A |
| Return on Equity | -51.3%-25.1pp | -45.1%-23.3pp | -24.1%-12.3pp | -99.3%-82.5pp | -26.2%-15.5pp | -21.8% | -11.8% | -16.8% |
| Return on Assets | -16.1%-0.1pp | -15.9%+1.9pp | -10.8%-0.8pp | -62.7%-48.5pp | -16.0%-6.4pp | -17.8% | -10.1% | -14.2%+21.8pp |
| Current Ratio | 9.42+3.8x | 9.93+4.7x | 11.94+5.5x | 5.61-0.6x | 5.66-3.3x | 5.23 | 6.47 | 6.21+3.6x |
| Debt-to-Equity | N/A | N/A | N/A | 0.32 | 0.37 | N/A | N/A | N/A |
| Liabilities-to-Equity | 2.18+1.5x | 1.84+1.6x | 1.23+1.1x | 0.58+0.4x | 0.64+0.5x | 0.22 | 0.17 | 0.18 |
| Asset Turnover | 0.010.0x | 0.000.0x | N/A | 0.00 | 0.000.0x | 0.00 | 0.03 | N/A |
| FCF Margin | -579.9% | -5723.7% | N/A | N/A | N/A | N/A | -370.7% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Zenas BioPharma, Inc. ZBIO | FY2025 | $10.0M | -$377.7M | N/A | $1.8B | 37/100 |
| Zymeworks Inc. ZYME | FY2025 | $106.0M | -$81.1M | -76.6% | $1.8B | 79/100 |
| Trevi Therapeutics, Inc. TRVI | FY2025 | N/A | -$42.8M | N/A | $1.9B | — |
| Maze Therapeutics, Inc. MAZE | FY2025 | N/A | -$131.1M | N/A | $1.7B | — |
| Sarepta Therapeutics, Inc. SRPT | FY2025 | $2.2B | -$713.4M | -32.5% | $1.6B | 42/100 |
| Harmony Biosciences Holdings, Inc. HRMY | FY2025 | $868.5M | $158.7M | 18.3% | $1.9B | 87/100 |
Where Zenas BioPharma, Inc. Ranks
Frequently Asked Questions
Zenas BioPharma, Inc. (ZBIO) reported $10.0M in total revenue for fiscal year 2025. This represents a 100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Zenas BioPharma, Inc. (ZBIO) revenue grew by 100.0% year-over-year, from $5.0M to $10.0M in fiscal year 2025.
No, Zenas BioPharma, Inc. (ZBIO) reported a net loss of $377.7M in fiscal year 2025.
Zenas BioPharma, Inc. (ZBIO) had EBITDA of -$383.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Zenas BioPharma, Inc. (ZBIO) had $110.6M in cash and equivalents against $78.6M in long-term debt.
Zenas BioPharma, Inc. (ZBIO) has a return on equity of -156.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Zenas BioPharma, Inc. (ZBIO) recorded an outflow of $172.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Zenas BioPharma, Inc. (ZBIO) recorded an outflow of $172.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Zenas BioPharma, Inc. (ZBIO) had $383.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Zenas BioPharma, Inc. (ZBIO) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Zenas BioPharma, Inc. (ZBIO) invested $168.1M in research and development during fiscal year 2025.
Zenas BioPharma, Inc. (ZBIO) had a current ratio of 5.61 as of fiscal year 2025, which is generally considered healthy.
Zenas BioPharma, Inc. (ZBIO) had a debt-to-equity ratio of 0.32 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Zenas BioPharma, Inc. (ZBIO) had a liabilities-to-equity ratio of 0.58 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Zenas BioPharma, Inc. (ZBIO) had a return on assets of -98.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Zenas BioPharma, Inc. (ZBIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.8B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Zenas BioPharma, Inc. (ZBIO) trades at 179x sales, its market capitalization divided by $10.0M revenue, FY2025. The market capitalization is $1.8B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Zenas BioPharma, Inc. (ZBIO) held $360.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $172.3M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Zenas BioPharma, Inc. (ZBIO) has an Altman Z-Score of 2.44, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Zenas BioPharma, Inc. (ZBIO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Zenas BioPharma, Inc. (ZBIO) reported a net loss of $377.7M while operations used $172.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Zenas BioPharma, Inc. (ZBIO) reported an operating loss of $383.1M against $7.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Zenas BioPharma, Inc. (ZBIO) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.